The Journal of pharmacology and experimental therapeutics
November 2011
Gregory C Hadlock, Katy M Webb, Lisa M McFadden et al.
The designer stimulant 4-methylmethcathinone (mephedrone) is among the most popular of the derivatives of the naturally occurring psychostimulant cathinone. Mephedrone has been readily available for legal purchase both online and in some stores and has been promoted by aggressive Web-based marketing. Its abuse in many countries, including the United States, is a serious public health concern....
European Journal of Pharmacology
February 25, 2000
M E Alburges, B P Ramos, L Bush et al.
21 citations
Ibogaine is an indolamine found in the West Africa shrub, Tabernanthe iboga, and has been proposed for the treatment of addiction to central nervous system (CNS) stimulants such as cocaine and amphetamine. The mechanism of ibogaine action and its suitability as a treatment for drug addiction still remains unclear. Since previous studies demonstrated differential effects of stimulants of abuse...
Brain Research
November 13, 1999
M E Alburges, G R Hanson
11 citations
Ibogaine (Endabuse) is a psychoactive indole alkaloid found in the shrub, Tabernanthe iboga, which has been used to treat stimulant addiction. Because ibogaine influences the activity of neurotensin systems, a dopamine-linked neuropeptide, the present study investigated if ibogaine also influences dynorphin (DYN) pathways. Unlike neurotensin responses, ibogaine alone did not alter DYN levels in...
Brain Research
February 6, 1999
M E Alburges, G R Hanson
18 citations
Ibogaine (Endabuse) is a psychoactive indole alkaloid found in the West African shrub, Tabernanthe iboga. This drug interrupts cocaine and amphetamine abuse and has been proposed for treatment of addiction to these stimulants. However, the mechanism of action that explains its pharmacological properties is unclear. Since previous studies demonstrated differential effects of psychotomimetic...
Journal of Pharmacology and Experimental Therapeutics
May 1, 1992
Michel Johnson, I. Elayan, G. R. Hanson et al.
The effects of 3,4-dihydroxymethamphetamine (DHM) and 2,4,5-trihydroxymethamphetamine (THM) on central serotonergic and dopaminergic systems were investigated to determine if these metabolites share the neurochemical properties of 3,4-methylenedioxymethamphetamine. THM (50-200 micrograms) or DHM (135 micrograms) was administered i.c.v. to rats; 5 days later, cortical, striatal and hippocampal...
Journal of Neurochemistry
August 1, 1989
Donna M. Stone, Glen R. Hanson, James W. Gibb
Abstract: The activity of tryptophan hydroxylase (EC 1.14.16.4) from rat brain was significantly decreased 1 h following a single systemic injection of 3,4‐methylenedioxy‐methamphetamine (MDMA) when assessed ex vivo by ra‐dioenzymatic assay or in vivo by the quantitation of 5‐hy‐droxytryptophan accumulation following central L‐aromatic amino acid decarboxylase inhibition. Recovery of enzymatic...
Journal of Pharmacology and Experimental Therapeutics
October 1, 1988
D. M. Stone, Michel Johnson, G. R. Hanson et al.
Similar to other amphetamine analogs 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy"), a currently popular illicit drug, has been characterized recently as a serotonergic neurotoxin due to its ability to cause long-lasting deficits in markers of central serotonergic function in animals. Because the serotonergic toxicity associated with the MDMA analog methamphetamine has been linked...
Journal of Pharmacology and Experimental Therapeutics
March 1, 1988
Michel Johnson, A. Letter, Kalpana M. Merchant et al.
This study demonstrates that the isomers of 3,4-methylenedioxyamphetamine (MDA) and 3,4-methylenedioxymethamphetamine (MDMA) are different in their ability to induce changes in serotonergic parameters and nigral concentrations of neurotensin-like immunoreactivity. With five successive doses (3.5 mg/kg) the d-MDA isomer was more potent than the l-MDA in its ability to decrease the concentrations...
Neuropharmacology
December 1987
D M Stone, K M Merchant, G R Hanson et al.
In the rat, administration of the psychoactive analog of amphetamine 3,4-methylenedioxymethamphetamine (MDMA), causes selective, pronounced decreases in markers of central serotonergic function. The time course of these neurochemical changes was examined in several serotonergic nerve terminal regions of the brain. Fifteen min after subcutaneous injection of MDMA (10 mg/kg), the enzymatic...